ANKTIVA (N-803) Plus BCG for BCG-Unresponsive NMIBC

ANKTIVA (N-803) Plus BCG for BCG-Unresponsive NMIBC is a conventional oncology treatment or care pathway used within standard cancer care, usually under the direction of oncology specialists and with disease-specific indications. In cancer care, it should be evaluated by evidence level, intended use, safety, interactions, and whether it is being used as conventional treatment, supportive care, an experimental adjunct.